Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 23, 2024Journal of Medical EconomicsOpen Access

Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England

View Full Paper
Ask AI
Bookmark
Share

Authors

TITariq IqbalNKNicholas A. KennedyADAnjan Dhar

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Iqbal et al. (2024) studied this question.

synapsesocial.com/papers/68e77de0b6db6435876f12aehttps://doi.org/10.1080/13696998.2024.2313932
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China2024 · 1 citations
  2. 2A Cost-utility Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China2024
  3. 3Casemix-based budget impact analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in the Netherlands2026
  4. 4Intravenous Ferric Carboxymaltose Versus Oral Ferrous Sulfate for Iron Deficiency Anemia: A Retrospective Cohort Study of Iron Store Repletion and Safety2026
  5. 5Treatment targeting pediatric inflammatory bowel disease-associated anemia: experience from a single tertiary center2025